The Claim
Intermittent administration of dasatinib plus quercetin for 20 weeks in postmenopausal women transiently increases the bone formation marker P1NP by 16% at 2 and 4 weeks, but this increase is not sustained at 20 weeks.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In postmenopausal women, taking dasatinib and quercetin together in intermittent doses for 20 weeks causes a 16% rise in the bone formation marker P1NP at 2 and 4 weeks, but this rise disappears by 20 weeks.
See the scientific wording
Intermittent dasatinib plus quercetin administration for 20 weeks in postmenopausal women transiently increases the bone formation marker P1NP by 16% at 2 and 4 weeks in the overall group, but this effect is not sustained at 20 weeks, indicating a short-lived stimulation of bone formation without long-term impact.
Dead or aging bone cells are removed, which lowers a protein that blocks bone growth signals. This allows bone-building cells to become more active and make more bone for a few weeks, but the effect stops after the initial burst because the bone cells return to their normal state.
What the research says
1 studyIn older women, a short course of two drugs temporarily boosted a sign of new bone growth by 16% for the first few weeks, but that boost disappeared after 20 weeks — just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.